Analyst Ratings For Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Today, William Blair reiterated its Outperform rating on Portola Pharmaceuticals Inc (NASDAQ:PTLA).
There are 4 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Portola Pharmaceuticals Inc (NASDAQ:PTLA) is Buy with a consensus target price of $35.50 per share, a potential 65.89% upside.
Some recent analyst ratings include
- 12/12/2018-Portola Pharmaceuticals Inc (NASDAQ:PTLA) had its Outperform rating reiterated by William Blair
- 8/9/2018-Portola Pharmaceuticals Inc (NASDAQ:PTLA) had its Buy rating reiterated by Cowen
- 12/1/2017-Portola Pharmaceuticals Inc (NASDAQ:PTLA) has coverage initiated with a Buy ➝ Buy rating and $75.00 price target
- On 8/23/2018 Jeffrey W Bird, Director, bought 390,000 with an average share price of $25.84 per share and the total transaction amounting to $10,077,600.00.
- On 8/21/2018 Jeffrey W Bird, Director, bought 137,563 with an average share price of $25.17 per share and the total transaction amounting to $3,462,460.71.
- On 6/6/2018 William Lis, CEO, sold 5,113 with an average share price of $45.21 per share and the total transaction amounting to $231,158.73.
- On 3/12/2018 Tao Fu, EVP, sold 1,135 with an average share price of $38.47 per share and the total transaction amounting to $43,663.45.
- On 12/15/2017 Henry Ward Wolff, Director, sold 12,000 with an average share price of $47.00 per share and the total transaction amounting to $564,000.00.
- On 7/18/2017 John T. Curnutte, Insider, sold 10,000 with an average share price of $65.00 per share and the total transaction amounting to $650,000.00.
- On 7/18/2017 Tao Fu, EVP, sold 5,812 with an average share price of $65.00 per share and the total transaction amounting to $377,780.00.
About Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Portola Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. The company's two FDA-approved medicines are Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor candidate for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Dermavant Sciences GmbH; and Ora, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.
Recent Trading Activity for Portola Pharmaceuticals Inc (NASDAQ:PTLA)
Shares of Portola Pharmaceuticals Inc closed the previous trading session at 21,33 up +1,83 9,38 % with 660839 shares trading hands.